Aequs IPO Subscription Status Day 1 LIVE: Issue Booked 1.04x, GMP At 35%, Step-By-Step Application Process Explained
Aequs IPO Subscription Status Day 1 is off to a strong start, with the issue receiving healthy demand within the first trading hours. Backed by a price band of ₹118–₹124 and an issue size of ₹922 crore, the IPO is drawing attention from retail and institutional investors alike.

With the Aequs IPO GMP Today hovering around a robust premium, market sentiment appears optimistic as investors evaluate listing gains and long-term potential.
What are the IPO Details for Aequs Limited?
Here’s a quick snapshot of the IPO at a glance:
| Parameter | Detail |
|---|---|
| IPO Open Date | 3 December 2025 |
| IPO Close Date | 5 December 2025 |
| Price Band | ₹118 – ₹124 per share |
| Lot Size (Min) | 120 shares |
| Minimum Retail Investment | ≈ ₹14,880 (at upper price band) |
| Issue Size (Fresh + OFS) | ≈ ₹921.81 crore |
| Allocation (QIB : NII : Retail) | 75% : 15% : 10% (standard main-board split) |
| Expected Allotment Date | 8 December 2025 |
| Tentative Listing Date (BSE & NSE) | 10 December 2025 |
So, by now (Day-1), investors are busy placing bids — and the numbers look interesting.
How is the Aequs IPO Subscription Status & What’s the GMP Today?
- As per the Aequs IPO Subscription Status on Day 1, the issue reportedly got booked 50% within the first hour of launch, underscoring healthy investor interest.
- As for grey-market whisperings: the Grey Market Premium (GMP) for Aequs is currently at ₹46.5 per share — which puts the grey-market listing price at around ₹170.5/share, a premium of ~37.5% over the issue price.
What Does GMP Signal?
GMP is an unofficial marker of pre-listing demand — basically, what buyers are willing to pay even before the shares are out on the exchange.
A high GMP — like what we see for Aequs — often suggests strong bullish sentiment, hinting at potential listing-day gains. But prudent investors treat GMP as a soft signal, not a guarantee.
How to Apply for Aequs IPO (Step-by-Step)
- Open or log in to your Demat + trading account.
- Under the IPO section, select Aequs IPO.
- Choose number of lots (min 1 lot = 120 shares).
- Specify the bid price (within price band: ₹118–₹124).
- Submit and ensure funds are available to block the amount (e.g., ₹14,880 for 1 lot at upper band).
- After IPO closes (5 Dec), check allotment status (tentatively 8 Dec), and if allotted — shares get credited (likely 9 Dec), else refund.
Expert View: Is Aequs IPO a Good Bet?
Market watchers and analysts see a few factors working in favour of Aequs:
- The company offers fully vertically integrated aerospace manufacturing in a Special Economic Zone (SEZ) — rare in India — giving it a unique competitive edge.
- Diversified business: besides aerospace, Aequs serves consumer-electronics, plastics and home-appliance segments — providing a cushion against cyclicality.
- Given the strong GMP and early subscription trend, short-term listing pop seems likely, which might attract retail interest.
Should You Apply for Aequs IPO?
If you are a short-term investor — aiming to benefit from potential listing gains — Aequs IPO looks tempting given the strong GMP and early subscription momentum.
If you are a long-term investor — and believe in India’s aerospace manufacturing potential and Aequs’ diversified business model — applying could be a good move, provided you’re comfortable with risks.
That said — avoid bidding at unreasonably high prices on mere hype. Use GMP as a guide, but also weigh fundamentals and your risk appetite.
Conclusion:
With current buzz around good Aequs IPO subscription status and a lofty grey-market premium — this issue appears to be among the hotter IPOs of the season. If the listing unfolds as per GMP whispers, early gains are plausible. But make a balanced decision — combining market sentiment, company fundamentals, and your own investment horizon.
Click Here to know more market & IPO related news and updates.
Disclaimer: The views and investment insights provided here are based on publicly available information and do not constitute financial advice. Readers are advised to conduct their own research or consult certified financial experts before making investment decisions.



